Course

Treatment Trends in Rheumatoid Arthritis

0 out of 2 steps completed0%
0 Lessons

Treatment Trends in Rheumatoid Arthritis

Learning Objectives

  1. Identify key steps in the treat-to-target algorithm that are intended to more tightly control RA patients’ disease activit
  2. Determine which RA patient cohorts, if any, would benefit from drug tapering or discontinuation of specific treatment regimens
  3. Select new therapeutic targets under investigation in late-stage clinical trials of biologic therapies being developed for possible use in patients with RA
  4. Discuss current concerns surrounding the potential introduction of biosimilars for RA patients in the United States

Disclosure

It is the policy of the Rheumatology Nurses Society (RNS) that the education presented within RNS-provided activities be unbiased and based upon scientific evidence. To help participants make judgments about the presence of bias, RNS provides information that planners, teachers, authors, developers, and activity managers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this educational activity. Relationships that an individual may have with commercial entities have been disclosed and reviewed, and any potential conflicts have been resolved.

Relationships are abbreviated as follows:
E, Educational planning committee;
G, Grant/ research support recipient;
A, Advisor/review panel member;
C, Consultant;
S, Stock shareholder;
SB, Speaker bureau;
PE, Promotional event talks;
H, Honoraria;
O, Other.

Sheree Carter, PhD, RN has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Celgene, Antares, Amgen/A.

Jacqueline Fritz, RN, MSN, CNS has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: GlaxoSmithKline/A, Celgene, AbbVie/SB.

Elizabeth Kirchner, CNP has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Iroko, Amgen, Sanofi, Pfizer/A, Crescendo Biosciences/SB.

Iris Zink, MSN, NP has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: AbbVie/A,SB; Celgene, Sanofi/A; Antares/C: Bristol Myers-Squibb/SB.

Target Audience

rheumatology advanced practice nurses, and infusion nurses.

Content Direction

Scott Kober, MBA, Principal, MedCaseWriter, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Content Freelancer

Anne Jacobson, MPH, CCMEP, Medical Writer, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Content Peer Reviewer

This newsletter was reviewed by Linda Grinnell-Merrick, MS, NP-BC. Ms. Grinnell-Merrick has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Celgene/A,SB; GlaxoSmithKline, Amgen, Iroko/A.

Production Management

Kevin D. Lyons, Executive Director of the Rheumatology Nurses Society and Chief Executive Officer of Lyons Den Solutions, LLC, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Product Disclosure

This educational activity includes discussion of published and/or investigational uses of agents that are not indicated by the U.S. Food and Drug Administration. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The educational content of this activity has been peer reviewed and validated to ensure that it is a fair and balanced representation of the topic, based on the best available evidence.